RxDoctor Payments Data

Richard Shelton, MD

Clinical Cardiac Electrophysiology · Salt Lake City, UTNPI 1770741886

Payments from drug & device makers

What this record shows

This record is dominated by grants: $42,000 of the $46,943 with a category attached, or 89.5%. Medtronic accounts for 61.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $41,005 and has fallen 97.5% since, to $1,034 in 2025.

$46,943in general payments, 2019–2025

Across 60 payments — averaging $782.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Boston Scientific$16K
  • Abbott$1K
  • Cvrx, Inc.$261
  • Biotronik Inc.$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$93
  • plus $301 from 9 others

What the payments were for

  • Grants$42,00089%
  • Travel & lodging$2,1275%
  • Food & beverage$2,5365%
  • Education$2791%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,943 in reported general payments places this provider in the 65th percentile of 29 clinical cardiac electrophysiology providers in Utah.

See all clinical cardiac electrophysiology providers in Utah

Medicare billing

Part B allowed, 2024
$2,597
Medicare patients
17
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CorlanorIvabradine Hcl24$14,698
Cromolyn Sodium33$6,694
Pyridostigmine Bromide14$2,550
Midodrine Hcl11$1,326
Propranolol Hcl34$726
Metoprolol Tartrate16$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenCorlanor$62$14,69824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 clinical cardiac electrophysiology providers in Utah.

Other clinical cardiac electrophysiology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →